H. Lee Moffitt Cancer Center & Research Institute

Find a Researcher

Steven S. Brem, MD

Steven S. Brem, MD

Faculty Rank:

Senior Member

Titles:

  • Chair, Department of Neuro Oncology
  • Chief, Neurosurgery Service
  • Director, Neuro-Oncology Research Laboratory
  • NABTT (New Approaches to Brain Tumor Therapy) Investigator

Department/Program Affiliations:

  • Neuro-Oncology  
  • Experimental Therapeutics  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Consultation/Referral Phone:

(813) 745-3063

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences
  • Medicine / Neurosurgery
  • Medicine / Neurology
  • Medicine / Molecular Pharmacology & Physiology

University Academic Rank:

Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Steven S. Brem, MD

Education & Training:

  • M.D., Harvard Medical School, Boston, MA, 1972
  • Internship, Massachusetts General Hospital, 1973 - General Surgery
  • Residency, Massachusetts General Hospital, 1981 - Neurosurgery
  • Fellowship, New York Hospital, Cornell Medical Center, 1980 - Neurosurgery

General Board Certification / SubSpecialty:

  • Neurology
  • Neurological Surgery

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Steven S. Brem, MD

Research Interests:

Frameless image-guided surgery, surgery of brain metastasis and malignant tumors, experimental therapeutics, anti-angiogenesis therapies, pituitary surgery, skull base surgery.



For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Steven S. Brem, MD

Publications:

  1. Paris D, Ganey N, Banasiak M, Laporte V, Patel N, Mullan M, Murphy SF, Yee GT, Bachmeier C, Ganey C, Beaulieu-Abdelahad D, Mathura VS, Brem S, Mullan M. Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease. J Neurosci. 2010 Aug;30(34):11251-11258. Pubmedid: 20739545.   Pubmed ID: 20739545

  2. Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb;16(2):195-202. Pubmedid: 19097905.   Pubmed ID: 19097905

  3. Brem S, Bierman P, Black P, Brem H, Chamberlain M, Chiocca E, DeangelisLM, Fenstermaker R, Friedman A, Gilbert M, Glass J, Grossman S, Heimberger A, Junck L, Linette G, Loeffler J, Maor M, Moots P, Mrugala M, Nabors L, NewtonHB, Olivi A, Portnow J, Prados M, Raizer J, Shrieve D, Sills AK J. Central nervous system cancers. J Natl Compr Canc Netw. 2008 May;6(5):456-504. Pubmedid: 18492461.   Pubmed ID: 18492461

  4. Ewend M, Morris D, Carey L, Ladha A, Brem S. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Canc Netw. 2008 May;6(5):505-513. Pubmedid: 18492462.   Pubmed ID: 18492462

  5. Wong E, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw. 2008 May;6(5):515-522. Pubmedid: 18492463.   Pubmed ID: 18492463

  6. Barami K, Grow A, Brem S, Dagnew E, Sloan A. Vascular complications after radiosurgery for meningiomas. Neurosurg Focus. 2007 Mar;22(3):E9-E9. Pubmedid: 17608362.   Pubmed ID: 17608362

  7. Ewend M, Brem S, Gilbert M, Goodkin R, Penar P, Varia M, Cush S, Carey L. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res. 2007 Jun;13(12):3637-3641. Pubmedid: 17575228.   Pubmed ID: 17575228

  8. Lee H, Kim D, Dan HC, Wu EL, Gritsko TM, Cao C, Nicosia SV, Golemis EA, Liu W, Coppola D, Brem SS, Testa JR, Cheng JQ. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol. 2007 Mar;27(6): 2103-2119. Pubmedid: 17210637.   Pubmed ID: 17210637

  9. Wong E, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007 Oct;25(30):4705-4706. Pubmedid: 17947716.   Pubmed ID: 17947716

  10. Fruehauf J, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 2006 Aug;12(15):4523-4532. Pubmedid: 16899598.   Pubmed ID: 16899598

  11. Khan M, Andrews S, Ismail-Khan R, Munster P, Brem S, King J, Reintgen D, Sondak V, Daud A. Overall and progression-free survival in metastatic melanoma: analysis of asingle-institution database. Cancer Control. 2006 Jul;13(3):211-217. Pubmedid: 16885917.   Pubmed ID: 16885917

  12. Brem S, Bierman P, Black P, Blumenthal D, Brem H, Chamberlain M, Chiocca E, DeAngelis L, Fenstermaker R, Fine H, Friedman A, Glass J, Grossman S, Heimberger A, Junck L, Levin V, Loeffler J, Maor M, Narayana A, Newton H, Olivi A, Portnow J, Prados M, Raizer J, Rosenfeld S, Shrieve D, Sills AK J, Spence A, Vrionis F. Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Oct;3(5):644-690. Pubmedid: 16194456.   Pubmed ID: 16194456

  13. Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, Mikkelsen T, Fisher JD. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol. 2005 Jul;7(3):246-253. Pubmedid: 16053699.   Pubmed ID: 16053699

  14. Brem S, Panattil J. An era of rapid advancement: diagnosis and treatment of metastatic brain cancer. Neurosurgery. 2005 Nov;57:S5-S9. Pubmedid: 16237289.   Pubmed ID: 16237289

  15. Gallia G, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw. 2005 Sep;3(5):721-728. Pubmedid: 16194460.   Pubmed ID: 16194460

  16. Young R, Sills A, Brem S, Knopp E. Neuroimaging of metastatic brain disease. Neurosurgery. 2005 Nov;57(5):S10-S23. Pubmedid: 16237282.   Pubmed ID: 16237282

  17. Brem S, Horton J. Basis for progress in brain tumor therapy. Cancer Control. 2004;11(3):142-142. Pubmedid: 15153837.   Pubmed ID: 15153837

  18. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon D, Crescentini R, Abdullah L, Coppola D, Rojiani A, Crawford F, Sebti S, Mullan M. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004;7(1):75-85. Pubmedid: 15302999.   Pubmed ID: 15302999

  19. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res. 2004 May;64(10):3586-3592. Pubmedid: 15150116.   Pubmed ID: 15150116

  20. Baker M, Brem S, Daniels S, Sherman B, Phuphanich S. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol. 2002;59(3):239-242. Pubmedid: 12241121.   Pubmed ID: 12241121

  21. Jennings J, Rojiani A, Brem S, Murtagh F. Necrotizing neurosarcoidosis masquerading as a left optic nerve meningioma: case report. Ajnr Am J Neuroradiol. 2002;23(4):660-662. Pubmedid: 11950662.   Pubmed ID: 11950662

  22. Vrionis F, Saatman D, Sorenson J, Brem S. Microscopic paraseptal sphenoidotomy approach for pituitary tumors. Cancer Control. 2002;9(3):223-231. Pubmedid: 12060820.   Pubmed ID: 12060820

  23. Brem S. Angiogenesis antagonists: curent clinical trials. Angiogenesis. 1999;2:9-20.  

  24. Brem, S. Angiogensesis and cancer control: from concept to therapeutic trial. Cancer Control. 1999 Oct;6(5):436-458. Pubmedid: 10758576.   Pubmed ID: 10758576

  25. Brem S. Brain tumor therapy: new lights on the horizon. Cancer Control. 1998;5:95-97. Pubmedid: 10761020.   Pubmed ID: 10761020

  26. Brem S. Ten best readings on brain tumors. Cancer Control. 1998;5:177-178. Pubmedid: noPMID.  

  27. Clarke L, Velthuizen R, Clark M, Gaviria G, Hall L, Goldgof D, Murtagh R, Phuphanich S, Brem S. MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magn Reson Imaging. 1998;16(3):271-279. Pubmedid: 9621968.   Pubmed ID: 9621968

  28. Davis F, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg. 1998;88:1-10. Pubmedid: 9420066.   Pubmed ID: 9420066

  29. Fernandez P, Brem S. Malignant brain tumors in the elderly. Clin Geriatr Med. 1997;13(2):327-337. Pubmedid: 9115454.   Pubmed ID: 9115454

  30. Brem H, Piantadosi S, Burger P, Walker M, Selker R, Vick N, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold C. Placebo-controlled trail of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemothery for recurrent gliomas. Lancet. 1995;345:1008-1012. Pubmedid: 7723496.   Pubmed ID: 7723496

  31. Brem S, Rozental J, Moscal J. What is the etiology of human brain tumors? A report on the first Lebow Conference. Cancer. 1995;76:709-713. Pubmedid: 8625170.   Pubmed ID: 8625170

  32. Gately S, Tsanaclis A, Taklano S, Klagsbrun M, Brem S. Cells transfected with the basic fibroblast growth factor (bFGF) gene fused to a signal sequence are invasive in vitro and in situ in the brain. Neurosurgery. 1995;36:780-788. Pubmedid: 7596510.   Pubmed ID: 7596510

  33. Landau B, Kwaan H, Verrusio E, Brem S. Elevated levels of urokinase-type plasminogen activator and plasminogen activator type-1 in malignant human brain tumors. Cancer Res. 1994;54:2654-2660.  

  34. Takano S, Gately S, Engelhard H, Tsanaclis A, Brem S. Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neurooncol. 1994;21:189-201.  

  35. Takano S, Gately S, Jiang J, Brem S. A diaminoanthraquinone inhibitor of angiogenesis. J Pharm Exp Ther. 1994;271:1027-1033.  

  36. Takano S, Gately S, Neville M, Herblin W, Fross J, Engelhard H, Perricone M, Eidsvoog K, Brem S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroglast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 1994;54:2654-2660.  

  37. Comair Y, Schipper H, Brem S. Prevention of oxyhemoglobin-induced cytoskeletal injury in vascular endothelial and smooth muscle cells by deferoxamine. Neurosurgery. 1993;32:58-65.  

  38. Brem S, Tsanaclis A, Gross J, Herblin W. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer. 1992;70:2673-2680.  

  39. Garfinkle A, Dnays I, Nicolle D, Colohan A, Brem S. Terson's syndrome: a reversible cause of blindness following subarachnoid hemorrhage. J Neurosurg. 1992;76:771-776.  

  40. Brem S, Zagzag D, Tsanaclis A, Gately S, Elkouby M, Brien S. Inhibition of angiogenesis and tumor growth in the brain: suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol. 1990;137(5):1121-1142.  

Steven S. Brem, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Evaluating the Treatment Effect of Surgery Plus Gliadel Waver in Pts with Metastatic Brain Cancer
Sponsor: MGI Pharma, Inc.
Project Dates: November 30, 2007 to November 29, 2011
Earned to Date: $100,214

Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone inGBM
Sponsor: NovoCure, Ltd.
Project Dates: February 24, 2010 to February 23, 2012
Earned to Date: $21,379

p75 NTR is a Rational Drug Target for Malignant Glioma
Sponsor: Univ of Calgary / Ivy (Ben & Catherine) Fdtn
Project Dates: November 28, 2008 to October 31, 2011
Annual Direct Cost: $197,157
Annual Total Cost: $197,157
Project Total: $292,966

Researcher  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute